Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ABL1
Variant E255V
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ABL1 E255V lies within the protein kinase domain of the Abl1 protein (UniProt.org). E255V results in decreased enzymatic efficiency (kcat/Km) in an in vitro assay (PMID: 30684523), and has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL1 (PMID: 21562040, PMID: 15710326), but has not been fully biochemically characterized and therefore, its effect on Abl1 protein function is unknown.
Associated Drug Resistance Y
Category Variants Paths

ABL1 mutant ABL1 E255V

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005157.6
gDNA chr9:g.130862977A>T
cDNA c.764A>T
Protein p.E255V
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005157.6 chr9:g.130862977A>T c.764A>T p.E255V RefSeq GRCh38/hg38
NM_007313.3 chr9:g.130862920A>T c.764A>T p.E255V RefSeq GRCh38/hg38
NM_007313.2 chr9:g.130862920A>T c.764A>T p.E255V RefSeq GRCh38/hg38
NM_005157 chr9:g.130862977A>T c.764A>T p.E255V RefSeq GRCh38/hg38
NM_007313 chr9:g.130862920A>T c.764A>T p.E255V RefSeq GRCh38/hg38
NM_005157.5 chr9:g.130862977A>T c.764A>T p.E255V RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04160546 Phase II Aspirin + Ponatinib Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP) Active, not recruiting ESP 0
NCT03874858 Phase II Nilotinib Asciminib + Nilotinib De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE) Active, not recruiting ITA 0
NCT04793399 Phase Ib/II Atezolizumab + Bosutinib Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Terminated ESP 0